1h Free Analyst Time
Alcohol Addiction - Pipeline Review, H2 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Pipeline Review, H2 2020, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.
Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 10, 4, 21, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionAlcohol Addiction - Overview
Alcohol Addiction - Therapeutics Development
Alcohol Addiction - Therapeutics Assessment
Alcohol Addiction - Companies Involved in Therapeutics Development
Alcohol Addiction - Drug Profiles
Alcohol Addiction - Dormant Projects
Alcohol Addiction - Discontinued Products
Alcohol Addiction - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Alcohol Addiction, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Companies, H2 2020 (Contd..2), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Alcohol Addiction - Pipeline by Adial Pharmaceuticals Inc, H2 2020
- Alcohol Addiction - Pipeline by Amygdala Neurosciences Inc, H2 2020
- Alcohol Addiction - Pipeline by Aptinyx Inc, H2 2020
- Alcohol Addiction - Pipeline by Assuage Pharmaceuticals Inc, H2 2020
- Alcohol Addiction - Pipeline by Astraea Therapeutics LLC, H2 2020
- Alcohol Addiction - Pipeline by AstraZeneca Plc, H2 2020
- Alcohol Addiction - Pipeline by Avicanna Inc, H2 2020
- Alcohol Addiction - Pipeline by BioCorRx Inc, H2 2020
- Alcohol Addiction - Pipeline by Bioprojet SCR, H2 2020
- Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd, H2 2020
- Alcohol Addiction - Pipeline by Colorado Research Partners LLC, H2 2020
- Alcohol Addiction - Pipeline by Confluence Pharmaceuticals LLC, H2 2020
- Alcohol Addiction - Pipeline by Corcept Therapeutics Inc, H2 2020
- Alcohol Addiction - Pipeline by Curemark LLC, H2 2020
- Alcohol Addiction - Pipeline by Dicerna Pharmaceuticals Inc, H2 2020
- Alcohol Addiction - Pipeline by Eli Lilly and Co, H2 2020
- Alcohol Addiction - Pipeline by Kinnov Therapeutics SAS, H2 2020
- Alcohol Addiction - Pipeline by Kinoxis Therapeutics Pty Ltd, H2 2020
- Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2020
- Alcohol Addiction - Pipeline by Laboratorio Farmaceutico CT Srl, H2 2020
- Alcohol Addiction - Pipeline by Lohocla Research Corp, H2 2020
- Alcohol Addiction - Pipeline by Mapreg SAS, H2 2020
- Alcohol Addiction - Pipeline by Mind Medicine Inc, H2 2020
- Alcohol Addiction - Pipeline by Montisera Ltd, H2 2020
- Alcohol Addiction - Pipeline by Naprogenix Inc, H2 2020
- Alcohol Addiction - Pipeline by Omeros Corp, H2 2020
- Alcohol Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2020
- Alcohol Addiction - Pipeline by Orphomed Inc, H2 2020
- Alcohol Addiction - Pipeline by Osmotica Pharmaceutical Corp, H2 2020
- Alcohol Addiction - Pipeline by Palisades Therapeutics, H2 2020
- Alcohol Addiction - Pipeline by Pfizer Inc, H2 2020
- Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2020
- Alcohol Addiction - Pipeline by Sosei Heptares, H2 2020
- Alcohol Addiction - Pipeline by South Plains Biotechnology Inc, H2 2020
- Alcohol Addiction - Pipeline by Syntropharma Ltd, H2 2020
- Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2020
- Alcohol Addiction - Pipeline by VM Discovery Inc, H2 2020
- Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2020
- Alcohol Addiction - Dormant Projects, H2 2020
- Alcohol Addiction - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Alcohol Addiction - Dormant Projects, H2 2020 (Contd..2), H2 2020
- Alcohol Addiction - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Alcohol Addiction, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adial Pharmaceuticals Inc
- Amygdala Neurosciences Inc
- Aptinyx Inc
- Assuage Pharmaceuticals Inc
- Astraea Therapeutics LLC
- AstraZeneca Plc
- Avicanna Inc
- BioCorRx Inc
- Bioprojet SCR
- Chronos Therapeutics Ltd
- Colorado Research Partners LLC
- Confluence Pharmaceuticals LLC
- Corcept Therapeutics Inc
- Curemark LLC
- Dicerna Pharmaceuticals Inc
- Eli Lilly and Co
- Kinnov Therapeutics SAS
- Kinoxis Therapeutics Pty Ltd
- Kyorin Pharmaceutical Co Ltd
- Laboratorio Farmaceutico CT Srl
- Lohocla Research Corp
- Mapreg SAS
- Mind Medicine Inc
- Montisera Ltd
- Naprogenix Inc
- Omeros Corp
- Opiant Pharmaceuticals Inc
- Orphomed Inc
- Osmotica Pharmaceutical Corp
- Palisades Therapeutics
- Pfizer Inc
- SK Biopharmaceuticals Co Ltd
- Sosei Heptares
- South Plains Biotechnology Inc
- Syntropharma Ltd
- Tonix Pharmaceuticals Holding Corp
- VM Discovery Inc
- Zynerba Pharmaceuticals Inc
